Published in F1000 Med Rep on February 11, 2010
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep (2008) 6.02
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int (2008) 5.25
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med (2008) 3.33
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
The natural history of chronic hepatitis B virus infection. Hepatology (2009) 3.08
Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology (2007) 3.06
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology (2006) 2.63
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int (2008) 1.77
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology (2009) 1.57
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Hepatitis B knowledge, testing and vaccination levels in Chinese immigrants to British Columbia, Canada. Can J Public Health (2007) 1.48
[EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol (2009) 0.93